Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;64(6):6.
doi: 10.1167/iovs.64.6.6.

IMI-Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice-2022 Update

James S Wolffsohn  1 , Yasmin Whayeb  1 , Nicola S Logan  1 , Rebecca Weng  2 ; International Myopia Institute Ambassador Group*
Collaborators, Affiliations

IMI-Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice-2022 Update

James S Wolffsohn et al. Invest Ophthalmol Vis Sci. .

Erratum in

Abstract

Purpose: Surveys in 2015 and 2019 identified a high level of eye care practitioner concern/activity about myopia, but the majority still prescribed single vision interventions to young myopes. This research aimed to provide updated information.

Methods: A self-administered, internet-based questionnaire was distributed in 13 languages, through professional bodies to eye care practitioners globally. The questions examined awareness of increasing myopia prevalence, perceived efficacy and adoption of available strategies, and reasons for not adopting specific strategies.

Results: Of the 3195 respondents, practitioners' concern about the increasing frequency of pediatric myopia in their practices differed between continents (P < 0.001), being significantly higher in Asia (9.0 ± 1.5 of 10) than other continents (range 7.7-8.2; P ≤ 0.001). Overall, combination therapy was perceived by practitioners to be the most effective method of myopia control, followed by orthokeratology and pharmaceutical approaches. The least effective perceived methods were single vision distance undercorrection, spectacles and contact lenses, as well as bifocal spectacles. Practitioners rated their activity in myopia control between (6.6 ± 2.9 in South America to 7.9 ± 1.2/2.2 in Australasia and Asia). Single-vision spectacles are still the most prescribed option for progressing young myopia (32.2%), but this has decreased since 2019, and myopia control spectacles (15.2%), myopia control contact lenses (8.7%) and combination therapy (4.0%) are growing in popularity.

Conclusions: More practitioners across the globe are practicing myopia control, but there are still significant differences between and within continents. Practitioners reported that embracing myopia control enhanced patient loyalty, increasing practice revenue and improving job satisfaction.

PubMed Disclaimer

Conflict of interest statement

Disclosure: J.S. Wolffsohn, AOS (C), Aston Vision Sciences (S), Bausch & Lomb (C), Alcon (C, F), Allergan (F), CooperVision (C, F), CSIDryEye (C), DopaVision, Eyoto (S), Johnson & Johnson Vision (F), Rayner (F), M2C Pharmaceuticals (C, F), Medmont (C), Novartis (C, F), NuVision (C, F), Santen (C), Scope Ophthalmics (C, F), SightGlass (C, F), Théa (C, F), Topcon (F), The Eye Doctor (F), Wolffsohn Research Limited (S); Y. Whayeb, None; N.S. Logan, CooperVision (F, C), Dopavision (C), Essilor (C), Hoya (F, C), Ocumension (C), SightGlass (F, C); R. Weng, None

Disclosure: (C) Bausch & Lomb International (C), OcuDoc (C), Visioneering Technologies (S), Neurolens (C), Reopia (C)

Disclosure: Alcon Vision Care (C), Johnson & Johnson Vision (C)

Disclosure: None

Disclosure: None

Disclosure: None

Disclosure: None

Disclosure: Alcon Research (C), CooperVision (C), Corneagen (C), EssilorLuxottica (C), Euclid Systems (C), Eyenovia (C), Genentech (C), Johnson & Johnson Surgical (C), Johnson & Johnson Vision (C), Lentechs (C), Novartis (C), Oculus (C), Pentavision (C), Presbia (C), Vyluma (C), Ridgevue Publishing (O), Ridgevue Vision (O)

Disclosure: Alcon (C), EssilorLuxottica (C), CSO (C), Nikon Instruments (C), Esavision (C), TS LAC (R), DoctorLens (R), Solotica (R), ESA Ortho-K lens designer (P)

Disclosure: None

Disclosure: Johnson and Johnson (C), Spectrum International (C), CooperVision (C), Grupo Manejo de la Miopia Latam (S)

Disclosure: CooperVision Inc., Pleasanton, California (E)

Disclosure: Brien Holden Vision Institute (C)

Disclosure: Coopervision (C), Avizor (C), Alcon (C)

Disclosure: Alcon (C), CooperVision (C), EssilorLuxottica (C), Hoya Vision (C), Johnson & Johnson Vision (C), Menicon (C), SightGlass Vision (C), Topcon Healthcare (C), OCULUS (C), Visioneering Technologies (C), Vyluma (C)

Disclosure: None

Disclosure: None

Disclosure: None

Disclosure: None

Disclosure: European patent EP 3 271 392, JP 2021-119187, and US 2021 0340237 A1: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia

Disclosure: Alcon (C), Sightglass Vision (C), CooperVision Inc (C), Essilor (C)

Disclosure: None

Disclosure: Hoya (C), Zeiss (C), Omisan Farmaceutici (C), CooperVision (C), AOS Sparca (C), Easytears (C)

Disclosure: Santen (C), CooperVision (C)

Disclosure: None

Disclosure: Member of Advisory Board Lens Essilor Stellest (C); Founder of Optica Pérez Casas (O)

Disclosure: Alcon (F), Owner of contact-lenses.gr—distributor of Menicon in Greece (O)

Disclosure: None

Disclosure: Menicon, Japan (E)

Disclosure: None

Disclosure: CooperVision Specialty EyeCare EMEA (E)

Disclosure: None

Disclosure: None

Disclosure: CooperVision (S)

Disclosure: None

Disclosure: None

Figures

Figure 1.
Figure 1.
Level of concern (rated from 0 [low] to 10 [high]) regarding the perceived increasing frequency of pediatric myopia in their practice for practitioners located in different continents. N = 3017. Box = 1 SD; solid line = median; dashed line = mean; whiskers = 95% confidence interval.
Figure 2.
Figure 2.
Perceived level of clinical activity in myopia control (rated from 0 [low] to 10 [high]) for practitioners located in different continents. N = 3017. Box = 1 SD; solid line = median; dashed line = mean; whiskers = 95% confidence interval.
Figure 3.
Figure 3.
The minimum degree of myopia present in a child to warrant adoption of myopia management varied between continents. N = 3017.
Figure 4.
Figure 4.
Factors cited by practitioners in different continents for not adopting myopia control approaches. N = 3017.
Figure 5.
Figure 5.
Ranked criteria for starting myopia control in young progressing myopes. N = 3017. AC/A = accommodative-convergence to accommodation ratio; choroidal thickness ^ = choroidal thickness change.
See this image and copyright information in PMC

References

    1. Holden BA, Fricke TR, Wilson DA, et al. .. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016; 123: 1036–1042. - PubMed
    1. Sankaridurg P, Tahhan N, Kandel H, et al. .. IMI Impact of myopia. Invest Ophthalmol Vis Sci. 2021; 62: 2–2. - PMC - PubMed
    1. Resnikoff S, Jonas JB, Friedman D, et al. .. Myopia—A 21st century public health issue. Invest Ophthalmol Vis Sci. 2019; 60: Mi–Mii. - PMC - PubMed
    1. Wolffsohn JS, Kollbaum PS, Berntsen DA, et al. .. IMI—Clinical myopia control trials and instrumentation report. Invest Ophthalmol Vis Sci. 2019; 60: M132–M160. - PubMed
    1. Flitcroft DI, He M, Jonas JB, et al. .. IMI—Defining and classifying myopia: A proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019; 60: M20–M30. - PMC - PubMed

Publication types